[This Week's IPO] Demand Forecasting and Subscription Schedule for the First Week of March

In the first week of this month (March), Meju and Hanpass will conduct demand forecasting for institutional investors. Kanaph Therapeutics is preparing for a public subscription for retail investors.

<Demand Forecasting>

◆Meju= Meju possesses core competitiveness in precision biosignal measurement technology and on-device machine learning-based biosignal processing technology. Leveraging these strengths, the company has established the first commercial reference in the domestic market for mobile remote patient monitoring (aRPM), and has pioneered the market based on real-world experience centered on medical field applications.

The company plans to offer a total of 1,345,000 shares. The desired offering price per share ranges from 16,700 to 21,600 won, with the total expected offering amounting to approximately 22.4 billion won. The demand forecasting for institutional investors takes place from February 23 to 27, while the public subscription for retail investors is scheduled for March 5 to 6. Shinhan Investment Corp. is serving as the lead underwriter.

◆Hanpass= Hanpass is a company that provides financial services, including overseas remittance and daily convenience services, targeting foreign residents in Korea as its core customers via its proprietary application. It has established a financial infrastructure enabling remittances through over 50 global MTO networks and to over 200 countries. Based on its overseas remittance, easy remittance, mobile wallet, and prepaid card services, Hanpass also offers solutions in everyday life sectors such as mobility, job search, visa consultation, and insurance services.

The company will offer a total of 1,100,000 shares. The desired offering price per share ranges from 17,000 to 19,000 won. Based on the lower end of the price range, the total offering is estimated at 18.7 billion won. Demand forecasting will be held from March 6 to 12, followed by public subscription for retail investors on March 16 to 17. The lead underwriters are Korea Investment & Securities and Daishin Securities.

<Public Subscription for Retail Investors>

◆Kanaph Therapeutics= The desired offering price per share ranges from 16,000 to 20,000 won. The total expected offering amount is between 32 and 40 billion won. Demand forecasting was conducted through February 27, and the public subscription for retail investors is scheduled for March 5 to 6. The lead underwriter is Korea Investment & Securities.

Established in February 2019, Kanaph Therapeutics develops innovative new drugs using human genome-based drug development technology. In particular, the company continues to expand its pipeline to address the unmet medical needs of patients with solid tumors by developing bispecific antibody-based immuno-oncology drugs targeting the tumor microenvironment and immunomodulatory mechanisms, as well as ADC therapeutics utilizing next-generation ADC technology.

This content was produced with the assistance of AI translation services.